Every Form 4 that ProMIS Neurosciences Inc. (PMN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PMN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PMN filings page.
Johanne Kaplan, Chief Development Officer of ProMIS Neurosciences Inc., purchased 2,280 Common Shares on August 5, 2026 in a purchase classified as an open market or private transaction at $13.30 per share. After this transaction, Kaplan directly owns 6,221 Common Shares of the company.
ProMIS Neurosciences Inc. director William W. Wyman received two option awards to buy Common Shares. One grant covers 11,000 options at an exercise price of $10.77 per share, expiring on May 20, 2036. A second grant covers 5,500 options on the same terms.
According to the footnotes, one grant vests in full on May 20, 2027, while another vests with 25% upon grant and the remainder ratably over thirty-six months, in each case subject to continued service on the Board.
ProMIS Neurosciences Inc. director Eugene Williams reported receiving two option grants to buy common shares. On May 20, 2026, he was awarded options for 11,000 shares and 5,500 shares, each with an exercise price of $10.77 per share and expiring on May 20, 2036.
According to the footnotes, the 11,000-share option vests in full on May 20, 2027, subject to his continued service on the board. For the 5,500-share option, 25% vested upon grant and the remaining shares vest ratably over 36 months, also conditioned on continued board service. These are compensation-related awards, not open‑market purchases.
ProMIS Neurosciences Inc. reported that Chief Executive Officer Neil K. Warma received a grant of stock options. The award covers 160,000 options to buy common shares at an exercise price of $10.77 per share, expiring on May 20, 2036. According to the footnote, these options vest ratably over four years, contingent on his continued service with the company.
ProMIS Neurosciences Inc. director Madge K. Shafmaster reported two option awards that provide the right to buy common shares. One grant covers 11,000 underlying common shares at an exercise price of $10.7700 per share and expires on May 20, 2036.
According to the filing, another grant covers 5,500 underlying common shares at the same $10.7700 exercise price and the same expiration date. One option vests in full on May 20, 2027, while the other vests 25% at grant with the remaining shares vesting ratably over thirty-six months, in each case subject to continued service on the Board.
ProMIS Neurosciences Inc. reported that Chief Scientific Officer Neil Cashman received a grant of options to buy 50,000 Common Shares. These options have an exercise price of $10.77 per share and expire on May 20, 2036. The award was made at no cost to him and represents equity-based compensation rather than an open-market purchase or sale. According to a footnote, the options vest ratably over four years, contingent on his continued service with the company. Following this grant, he holds 50,000 options directly.
ProMIS Neurosciences Inc. reported that its Principal Accounting Officer, Max A. Milbury, received a compensation-related grant of stock options. The award covers 18,167 options to buy Common Shares at an exercise price of $10.77 per share, expiring on May 20, 2036. These options were granted at no cost and increase his directly held option position to 18,167 derivative securities. According to the disclosure, the options will vest ratably over four years, conditioned on his continued service with the company.
ProMIS Neurosciences Inc. reported that director Josh Mandel-Brehm received two option grants covering a total of 16,500 options to buy Common Shares. One grant covers 11,000 options at an exercise price of $10.77 per share, vesting in full on May 20, 2027, subject to continued Board service. The second grant covers 5,500 options at the same $10.77 exercise price, with 25% vesting immediately on grant and the remaining shares vesting ratably over 36 months, also tied to continued Board service. Both option awards expire on May 20, 2036, and represent compensation-related acquisitions rather than open-market purchases or sales.
ProMIS Neurosciences Inc. reported that Chief Development Officer Johanne Kaplan received a grant of options to acquire 50,000 Common Shares. The options have an exercise price of $10.77 per share and expire on May 20, 2036.
The award was granted at no cost and vests ratably over four years, subject to her continued service with the company. This filing reflects routine equity compensation and does not involve any open-market purchases or sales of the company’s shares.
ProMIS Neurosciences Inc. director Alex Slanix Paul reported receiving two grants of stock options. One award covers 11,000 options to buy Common Shares at an exercise price of $10.77 per share, expiring on May 20, 2036, that vest in full on May 20, 2027 subject to continued Board service. A second award covers 5,500 options at the same exercise price and expiration date, with 25% vesting immediately on grant and the remaining options vesting ratably over thirty-six months, also contingent on continued service.
ProMIS Neurosciences Inc. director Patrick D. Kirwin reported an open-market purchase of Common Shares through an associated professional corporation. The entity bought 4,000 shares at $11.33 per share, and now holds 4,653 shares indirectly. Kirwin also holds 5,135 shares directly and 305 shares indirectly through his spouse.
ProMIS Neurosciences Inc. director Williams Eugene reported an open-market purchase of company stock. He bought 2,000 Common Shares at a price of $24.40 per share, increasing his direct holdings to 12,397 Common Shares following the transaction.
ProMIS Neurosciences Inc. director Williams Eugene purchased a total of 4,000 Common Shares in open-market transactions over three days. He bought 1,000 shares at $22.53, 1,000 shares at $21.89, and 2,000 shares at $24.00. Following these purchases, he owns 10,397 Common Shares directly.
ProMIS Neurosciences Inc. Chief Development Officer Johanne Kaplan bought 1,629 common shares in an open-market purchase at $15.35 per share. After this transaction, Kaplan directly owns 3,941 common shares, modestly increasing personal equity exposure to the company.
ProMIS Neurosciences director and Chief Scientific Officer Neil Cashman reported an indirect purchase of 4,122 common shares at $12.13 per share through Research Capital Corporation, along with warrants to buy 4,122 additional common shares. These securities were acquired on February 3, 2026 under a Securities Purchase Agreement with selected investors.
The warrants to purchase common shares have an exercise price of $14.40 per share and are exercisable immediately. They will expire on the earlier of February 3, 2031 or within 60 days after a public announcement or Form 8-K filing of topline data from single ascending dose cohorts of PMN310. The filing also notes that common share figures reflect a one-for-twenty-five reverse split completed on November 28, 2025.
ProMIS Neurosciences Chief Development Officer Johanne Kaplan acquired equity on February 3, 2026. Kaplan bought 2,060 common shares at $12.13 per share and received warrants to purchase 2,060 additional common shares, also priced at $12.13 per common share and warrant under a Securities Purchase Agreement with selected investors.
After the transaction, Kaplan beneficially owned 2,312 common shares directly. The warrants have an exercise price of $14.40 per common share and become exercisable on February 3, 2026. They will expire on the earlier of February 3, 2031 or within 60 days after public announcement of topline data from PMN310 single ascending dose cohorts.
ProMIS Neurosciences Inc. insider transaction: Chief Executive Officer and director Neil K. Warma acquired 6,183 common shares of ProMIS Neurosciences Inc. on February 3, 2026 at a price of $12.13 per share. He also received warrants to purchase 6,183 common shares at an exercise price of $14.40 per share.
The warrants become exercisable on February 3, 2026 and will expire on the earlier of February 3, 2031 or within 60 days after a public announcement or Form 8-K filing of topline data from PMN310 single ascending dose cohorts.
ProMIS Neurosciences principal accounting officer Max A. Milbury reported purchasing additional equity in the company. On February 3, 2026, he acquired 6,595 common shares of ProMIS Neurosciences Inc. at a purchase price of $12.13 per share under a Securities Purchase Agreement with selected investors.
He also received common share purchase warrants to buy 6,595 additional common shares. These warrants are exercisable starting February 3, 2026 and will expire on the earlier of February 3, 2031 or within 60 days after a public announcement or Form 8-K filing of topline data from cohorts treated with single ascending doses of PMN310. Following the transaction, he beneficially owned 8,409 common shares and 6,595 warrants, all held directly.
ProMIS Neurosciences director Patrick D. Kirwin reported buying additional shares and warrants in the company. On February 3, 2026, he acquired 3,050 common shares and warrants to purchase 3,050 common shares under a Securities Purchase Agreement at $12.13 per share and warrant.
Following the transaction, he directly holds 5,135 common shares and warrants for 3,050 common shares with a $14.4 exercise price. He also indirectly beneficially owns 1,653 common shares through Patrick D. Kirwin Professional Corp and 305 common shares through his spouse. The filing notes a one-for-twenty-five reverse split completed on November 28, 2025, and states the warrants expire on the earlier of February 3, 2031 or within 60 days after topline PMN310 single ascending dose data is publicly announced.
ProMIS Neurosciences Inc. saw a group of Ally Bridge–affiliated investors report a new insider purchase. On February 3, 2026, they acquired 700,741 Common Shares of ProMIS at $12.13 per share, bringing their indirectly beneficially owned Common Shares to 943,090.
The investors also acquired Warrants to purchase 700,741 Common Shares, with a stated exercise price of $14.40. These Warrants are exercisable immediately and will expire on the earlier of within 60 days after a defined PMN310 topline-data Milestone Event or February 3, 2031.
The Common Shares and Warrants are held across Ally Bridge MedAlpha Master Fund L.P., ABG V-SIV IX Limited and ABG V-SIV X Limited, with ABG Management Ltd., Ally Bridge Group (NY) LLC, Fan Yu and director Alex Slanix Paul reported as sharing beneficial ownership through various control relationships.
ProMIS Neurosciences (PMN) reported an insider equity award on a Form 4. A director received an option to purchase 40,000 common shares at an exercise price of $0.45 per share on 10/22/2025, expiring on 10/22/2035. The option itself was granted for $0.
The filing states that 25% of the option vested on the grant date, with the remainder vesting in 36 equal monthly installments, subject to continued service. Following the transaction, 40,000 derivative securities were beneficially owned. The form was filed by more than one reporting person, and it notes that any proceeds from the sale of shares upon exercise will be remitted to Ally Bridge MedAlpha Master Fund L.P.
Insider purchase recorded by ProMIS Neurosciences (PMN). On 10/03/2025 Max A. Milbury, an officer serving as Principal Accounting Officer, acquired 30,392 common shares at $0.4912 per share. After the purchase he beneficially owned 45,389 shares. The Form 4 filed and signed on 10/06/2025 reports the transaction as a purchase by one reporting person and shows the ownership as direct. The filing supplies transaction price, share count, role of the reporting person, and post-transaction holdings.